A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis

New England Journal of Medicine

Volumn 324, Issue 22, 1991, Pages 1548-1554

  Poupon, Renée E ^a   Balkau, Beverley ^a   Eschwège, Eveline ^a   Poupon, Raoul ^b  

^a INSERM   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; PLACEBO; URSODEOXYCHOLIC ACID;

ADULT; BILIARY CIRRHOSIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0025876404     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199105303242204     Document Type: Article

References (44)

1. Kaplan M.M. Primary biliary cirrhosis. N Engl J Med 1987; 316:521-528
2. Markus B.H., Dickson E.R., Grambsch P.M., et al. Efficacy of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med 1989; 320:1709-1713
3. Triger D.R., Manifold I.H., Cloke P., Underwood J.C.E. D-penicillamine in primary biliary cirrhosis: two year results of a single centre, double-blind controlled trial. Gut 1980; 21:A919-A920. abstract.
4. Bassendine M.F., Macklon A.F., Mulcahy R., James O.F.W. Controlled trial of high and low dose D-penicillamine in primary biliary cirrhosis: results at three years. Gut 1982; 23:A909. abstract.
5. Epstein O., Jain S., Lee R.G., et al. D-penicillamine treatment improves survival in primary biliary cirrhosis. Lancet 1981; 1:1275-1277
6. Matloff D.S., Alpert E., Resnick R.H., Kaplan M.M. A prospective trial of D-penicillamine in primary biliary cirrhosis. N Engl J Med 1982; 306:319-326
7. Taal B.G., Schalm S.W., Ten Kate F.W.J., Van Berge Henegouwen G.P., Brandt K.-H. Low therapeutic value of D-penicillamine in a short-term prospective trial in primary biliary cirrhosis. Liver 1983; 3:345-352
8. Neuberger J., Christensen E., Portmann B., et al. Double blind controlled trial of D-penicillamine in patients with primary biliary cirrhosis. Gut 1985; 26:114-119
9. Bodenheimer H.C. Jr., Schaffner F., Sternlieb I., Klion F.M., Vernace S., Pezzullo J. A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis. Hepatology 1985; 5:1139-1142
10. Dickson E.R., Fleming T.R., Wiesner R.H., et al. Trial of penicillamine in advanced primary biliary cirrhosis. N Engl J Med 1985; 312:1011-1015
11. Heathcote J., Ross A., Sherlock S. A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology 1976; 70:656-660
12. Crowe J., Christensen E., Smith M., et al. Azathioprine in primary biliary cirrhosis: a preliminary report of an international trial. Gastroenterology 1980; 78:1005-1010
13. Christensen E., Neuberger J., Crowe J., et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final results of an international trial. Gastroenterology 1985; 89:1084-1091
14. Hoofnagle J.H., Davis G.L., Schafer D.F., et al. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 1986; 91:1327-1334
15. Mitchison H.C., Bassendine M.F., Malcolm A.J., Watson A.J., Record C.O., James O.F.W. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss. Hepatology 1989; 10:420-429
16. Minuk G.Y., Bohme C.E., Burgess E., et al. Pilot study of cyclosporin A in patients with symptomatic primary biliary cirrhosis. Gastroenterology 1988; 95:1356-1363
17. Wiesner R.H., Ludwig J., Lindor K.D., et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med 1990; 322:1419-1424
18. Kaplan M.M., Alling D.W., Zimmerman H.J., et al. A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 1986; 315:1448-1454
19. Warnes T.W., Smith A., Lee F.I., Haboubi N.Y., Johnson P.J., Hunt L. A controlled trial of colchicine in primary biliary cirrhosis: trial design and preliminary report. J Hepatol 1987; 5:1-7.
20. Bodenheimer H. Jr., Schaffner F., Pezzullo J. Evaluation of colchicine therapy in primary biliary cirrhosis. Gastroenterology 1988; 95:124-129
21. Poupon R., Chrétien Y., Poupon R.E., Ballet F., Calmus Y., Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1:834-836
22. Hoffman A.F. Bile acid hepatotoxicity and the rationale of UDCA therapy in chronic cholestatic liver disease: some hypotheses. In: Paumgartner G, Stiehl A, Barbara L, Roda E, eds. Strategies for the treatment of hepatobiliary diseases. Dordrecht, the Netherlands: Kluwer Academic, 1990: 13-33.
23. Poupon R.E., Eschwège E., Poupon R. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis: interim analysis of a double-blind multi-centre randomized trial. J Hepatol 1990; 11:16-21.
24. Stellaard F., Sackmann M., Sauerbruch T., Paumgartner G. Simultaneous determination of cholic acid and chenodeoxycholic acid pool sizes and fractional turnover rates in human serum using 13C-labeled bile acids. J Lipid Res 1984; 25:1313-1319
25. Dickson E.R., Grambsch P.M., Fleming T.R., Fisher L.D., Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10:1-7.
26. Ludwig J., Dickson E.R., McDonald G.S.A. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch [Pathol Anat] 1978; 379:103-112
27. Mehta C.R., Patel N.R., Tsiatis A.A. Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics 1984; 40:819-825
28. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481
29. Peto R., Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc [A] 1972; 135:185-207.
30. Cox D.R. Regression models and life tables. J R Stat Soc [B] 1972; 34: 187-220.
31. Dixon W.J., ed. BMDP statistical software. Berkeley: University of California Press, 1988.
32. Podda M., Battezzati P.M., Bertolini E., et al. Effects of ursodeoxycholic acid (UDCA) on liver function tests and bile acid metabolism in anicteric primary biliary cirrhosis (PBC): a dose–response study. Hepatology 1988; 8:1266. abstract.
33. Batta A.K., Arora R., Salen G., Katz S. Ursodeoxycholic acid improves liver function and reduces serum and urinary endogenous bile acids in primary biliary cirrhosis. Hepatology 1988; 8:1221. abstract.
34. Hadziyannis S., Hadziyannis E. A randomised controlled trial of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC). Hepatology 1988; 8:1421. abstract.
35. Leuschner U., Fischer H., Kurtz W., et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989; 97:1268-1274
36. Munoz S.J. Cyclosporine in primary biliary cirrhosis. N Engl J Med 1990; 323:1352.
37. Stiehl A., Raedsch R., Rudolph G. Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids. Gastroenterology 1990; 98:424-428
38. Marteau P., Chazouillères O., Myara A., Jian R., Rambaud J.-C., Poupon R. Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man. Hepatology 1991; 12:1206-1208
39. Kitani K. Hepatoprotective effect of ursodeoxycholate in experimental animals. In: Paumgartner G, Stiehl A, Barbara L, Roda E, eds. Strategies for the treatment of hepatobiliary diseases. Dordrecht, the Netherlands: Kluwer Academic, 1990: 43-56.
40. Tint G.S., Salen G., Shefer S. Effect of ursodeoxycholic acid and chenodeoxycholic acid on cholesterol and bile acid metabolism. Gastroenterology 1986; 91:1007-1018
41. Malavolti M., Fromm H., Ceryak S., Roberts I.M. Modulation of low density lipoprotein receptor activity by bile acids: differential effects of chenodeoxycholic and ursodeoxycholic acids in the hamster. J Lipid Res 1987; 28:1281-1295
42. Poupon R., Calmus Y. Bile acids and the immune system. In: Paumgartner G, Stiehl A, Gerok W, eds. Bile acids as therapeutic agents. Dordrecht, the Netherlands: Kluwer Academic (in press).
43. Calmus Y., Gane P., Rouger P., Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990; 11:12-15
44. Leuschner U., Dienes H.P., Güldütuna S., Birfkenfeld G., Leuschner M. Ursodeoxycholic acid (UDCA) influences immune parameters in patients with primary biliary cirrhosis (PBC). Hepatology 1990; 12:957. abstract.